ImmunityBio (NASDAQ:IBRX) Shares Gap Up to $4.94

ImmunityBio, Inc. (NASDAQ:IBRX) gapped up prior to trading on Tuesday . The stock had previously closed at $4.94, but opened at $6.15. ImmunityBio shares last traded at $5.05, with a volume of 15,358,833 shares trading hands.

Wall Street Analysts Forecast Growth

Separately, Piper Sandler boosted their target price on ImmunityBio from $4.00 to $5.00 and gave the company a “neutral” rating in a research note on Monday, March 25th.

ImmunityBio Price Performance

The business has a 50 day simple moving average of $5.20 and a 200 day simple moving average of $4.14.

ImmunityBio (NASDAQ:IBRX) last issued its earnings results on Tuesday, March 19th. The company reported ($0.19) EPS for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.01). The business had revenue of $0.14 million during the quarter, compared to analysts’ expectations of $0.03 million. As a group, equities research analysts forecast that ImmunityBio, Inc. will post -0.68 EPS for the current fiscal year.

Institutional Trading of ImmunityBio

Several large investors have recently made changes to their positions in IBRX. SG Americas Securities LLC bought a new stake in shares of ImmunityBio during the 3rd quarter worth about $57,000. Exchange Traded Concepts LLC boosted its stake in shares of ImmunityBio by 22.3% during the 3rd quarter. Exchange Traded Concepts LLC now owns 58,136 shares of the company’s stock worth $98,000 after acquiring an additional 10,596 shares in the last quarter. Aire Advisors LLC bought a new stake in shares of ImmunityBio during the 3rd quarter worth about $25,000. Stonehage Fleming Financial Services Holdings Ltd bought a new stake in shares of ImmunityBio during the 3rd quarter worth about $144,000. Finally, Merit Financial Group LLC lifted its position in shares of ImmunityBio by 84.0% during the 3rd quarter. Merit Financial Group LLC now owns 43,800 shares of the company’s stock worth $74,000 after purchasing an additional 20,000 shares during the last quarter. Institutional investors own 8.58% of the company’s stock.

ImmunityBio Company Profile

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in discovering, developing, and commercializing next-generation immuno- and cellular therapies for cancer and infectious diseases in the United States and Europe. The company offers immunotherapy and cell therapy platforms, including antibody cytokine fusion protein N-803, vaccine delivery technologies, and natural killer cell therapies.